BioArctic announced on November 2 that Novartis Pharma has terminated the option, collaboration and license agreement the two companies signed in August 2025. The deal paired BioArctic’s proprietary BrainTransporter technology, which uses the transferrin receptor to move drugs across the blood brain barrier, with an undisclosed Novartis antibody aimed at neurodegeneration.
BioArctic was explicit about the reason given. The termination follows a Novartis decision to discontinue the programme, and BioArctic said it is unrelated to the BrainTransporter technology. A Novartis spokesperson told BioSpace the decision followed a recent review of early research priorities to focus on where the company can have the greatest impact, and was unrelated to safety or efficacy concerns.
The financial consequence for BioArctic is limited and partly positive in the near term. It keeps the full 30 million dollar upfront payment and will recognise the remaining unrecognised portion as revenue in 2026. What it loses is the option value behind the deal, up to 772 million dollars in potential milestones plus tiered mid single digit royalties had a product reached the market.
BioArctic has signed five partnership agreements built on BrainTransporter, so the platform’s commercial test does not rest on this one programme. The signal in the termination is narrower: a large buyer reviewed its earliest stage neuroscience work 14 months into an option deal and chose to spend elsewhere.